New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

The Continuous Glucose Monitoring Market is Growing at a CAGR of 7.80%, Driven by the Increasing Prevalence of Prediabetes ...

Beta Bionics said the integration, which is scheduled to launch in the fourth quarter, will be the first of its kind for Freestyle Libre 3 Plus in the U.S. Abbott also has AID partnerships with ...

A series of case reports to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), describe how a technology giving insulin doses ...

Abbott’s latest diabetes device collaboration, the new partnership with ... “While Medtronic is unlikely to gain significant share in the CGM space with their own devices, they are not ...

Medtronic has already experienced success with the full market release of its related Simplera Sync sensor internationally, boding well for the U.S. launch of this new CGM. Medtronic will likely ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Tandem Diabetes is driving transformative innovation to help reduce the burden and create new possibilities ... as its CGM partners advance and drive the adoption of sensor technology.